ctDNA guiding adjuvant immunotherapy in urothelial carcinoma

Minimally invasive approaches to detect residual disease after surgery are needed to identify patients with cancer who are at risk for metastatic relapse. Circulating tumour DNA (ctDNA) holds promise as a biomarker for molecular residual disease and relapse 1 . We evaluated outcomes in 581 patients...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Nature (London) 2021-07, Vol.595 (7867), p.432-437
Hauptverfasser: Powles, Thomas, Assaf, Zoe June, Davarpanah, Nicole, Banchereau, Romain, Szabados, Bernadett E., Yuen, Kobe C., Grivas, Petros, Hussain, Maha, Oudard, Stephane, Gschwend, Jürgen E., Albers, Peter, Castellano, Daniel, Nishiyama, Hiroyuki, Daneshmand, Siamak, Sharma, Shruti, Zimmermann, Bernhard G., Sethi, Himanshu, Aleshin, Alexey, Perdicchio, Maurizio, Zhang, Jingbin, Shames, David S., Degaonkar, Viraj, Shen, Xiaodong, Carter, Corey, Bais, Carlos, Bellmunt, Joaquim, Mariathasan, Sanjeev
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!